Pulmonary Arterial Hypertension (PAH) Market Is Projected To Accelerate At A CAGR Of 5.4% To Reach Us$ 13.5 Bn By 2031

The pulmonary arterial hypertension (PAH) market was valued at US$ 5.2 billion in 2020 and is expected to grow at a 5.4% CAGR to US$ 13.5 billion by 2028.
Over the forecast period, demand for endothelin receptor antagonists (ERAs) is expected to grow at a 5% CAGR.

Read Report Overview: https://www.factmr.com/report/pulmonary-arterial-hypertension-pah-market

Competitive Landscape

Strategic formulations such as new product development and commercialization, commercial expansion, and distribution partnerships are being implemented by prominent participants for business expansion. Furthermore, these leaders are investing heavily in product development, which is fueling revenue generation.

As an example,

Teva Pharmaceutical Industries Ltd. launched a generic version of Gilead's Letairis (ambrisentan) tablets in the United States in 2019. Ambrisentan, an endothelin receptor antagonist, is used to treat pulmonary arterial hypertension.

To remain 'ahead' of your competitors, request for a sample: https://www.factmr.com/connectus/sample?flag=S&rep_id=7234

Key Segments Covered in Pulmonary Arterial Hypertension Industry Research

By Drug Class:

Prostacyclin & Prostacyclin Analogs

Endothelin Receptor Antagonists (ERAs)

Phosphodiesterase-5 (PDE-5) Inhibitors

Soluble Guanylate Cyclase (sGC) Stimulators

By Pipeline Analysis:

Early-stage Drug Candidates (Phase I & Phase II)

Late-stage Drug Candidates (Phase III & Registration Phase)

By Region:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Ask an Analyst: https://www.factmr.com/connectus/sample?flag=AE&rep_id=7234

Why is the market for pulmonary arterial hypertension in the United States expanding so quickly?

"The Presence of Board-Certified Physicians Increases Market Value"
Each year, pulmonary arterial hypertension causes over 200,000 hospitalizations in the United States. The availability of board-certified physicians, rising hospital admissions related to PAH, and the commercialization of new PAH medications, all accompanied by a promising pharmacological pipeline, are driving market growth in the United States.

Furthermore, the PAH market in the United States is expected to grow rapidly due to the rising prevalence of this illness as a result of heavy alcohol consumption, rapid adoption of a sedentary lifestyle, and rising smoking habits among individuals.

Pulmonary Arterial Hypertension (PAH) Market Competitive Analysis Market Report:

• Key players' strategies and products offered

• Potential and niche segments, geographical regions with promising growth

• A neutral perspective on market performance

• Must-have information for market players to sustain and expand their market footprint

Choose Quick and Secure PayPal Payment Mode to Get Full Access to This Report: https://www.factmr.com/checkout/7234

Why Should You Use Fact.MR?

1. A variety of analysis methods to provide precise market information.
2. Use of digital technologies to provide clients with up-to-date market solutions.
3. A multidisciplinary approach to providing accurate insights into various industries.
4. Gathering data from extensive primary and secondary research.
5. Availability around the clock to serve clients all over the world.

US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.